Business context and reporting period
The supplied filing is Dehaier Medical Systems Limited’s Form 20-F for the fiscal year ended December 31, 2015—not a Newegg Commerce, Inc. filing or a standalone 2015 Q4 report. It presents annual results, with 2014 figures restated and 2013 comparative figures. The company, based primarily in China, reported medical-device and mobile-health operations. In February 2016, it decided to discontinue traditional medical-device product lines and refocus on mobile medical devices, particularly sleep-respiratory and wireless health products.
Key financial metrics
Amounts are U.S. dollars unless stated otherwise.
| Metric | 2015 | 2014 (restated) |
|---|---|---|
| Revenue from continuing operations | $1.32 million | $2.77 million |
| Gross profit (loss) / margin | $(0.11) million / (8.7%) | $0.99 million / 35.8% |
| Operating loss | $(7.09) million | $(1.47) million |
| Net income (loss) from continuing operations | $(6.86) million | $0.92 million |
| Net income (loss) from discontinued operations | $(3.50) million | $(25.96) million |
| Consolidated net loss | $(10.36) million | $(25.03) million |
| Net loss attributable to Dehaier | $(10.22) million | $(24.30) million |
| Basic / diluted loss per share | $(1.74) / $(1.73) | $(4.41) / $(4.34) |
| Cash and cash equivalents at year-end | $0.62 million | $1.73 million |
| Working capital at year-end | $0.46 million | $9.74 million |
| Net cash from (used in) operating activities | $(2.34) million | $4.14 million |
| Net cash used in investing activities | $0.03 million | $11.20 million |
| Net cash provided by financing activities | $1.50 million | $6.26 million |
Year-end total assets were $13.84 million, total liabilities $6.53 million, and total equity $7.31 million. Current liabilities were $6.37 million. Short-term borrowings included $1.54 million of bank debt and $2.18 million due to a related party; the bank facility was secured by a building and guaranteed by the CEO and shareholders. The bank loan was due in December 2016 and had a stated 2016 floating rate of 7.2%. The CEO’s interest-free related-party loan had no stated maturity date.
Material changes versus prior periods
- Continuing-operations revenue fell 52% year over year, from $2.77 million to $1.32 million. Management attributed the decline to strategic retrenchment from traditional devices, market challenges, macroeconomic pressure, competition, and investment in sleep-respiratory products.
- Gross margin moved from 35.8% to negative 8.7%. Management said closing traditional production lines increased fixed costs allocated to remaining lines.
- General and administrative expense rose to $4.26 million from $1.95 million, and selling expense rose to $3.05 million from $0.23 million. The company attributed these increases mainly to R&D and market-development spending for sleep-respiratory business.
- Operating cash flow swung to a $2.34 million use from $4.14 million provided in 2014; cash declined by $1.10 million during 2015.
- 2014 was restated after the company identified understated receivable allowances, overstated prepayments and long-lived assets, and insufficient inventory reserves. Restated 2014 net loss attributable to Dehaier was $24.30 million versus previously reported net income of approximately $1.00 million; basic and diluted EPS each declined by $4.59 and $4.52, respectively, to losses of $4.41 and $4.34.
Outlook, risks, contingencies and unusual items
- Management said sleep-respiratory products were still at an early stage and had not generated significant sales in 2015. It expected this business to drive growth in 2016, but the filing provides no quantified revenue or earnings guidance. Management’s going-concern assessment relied in part on a six-year forecast and anticipated funding.
- A 2016 share-purchase agreement with Hangzhou Liaison Interactive provided for up to $20 million in equity financing at $1.80 per share. The filing reports a first closing of 620,414 shares for $1.12 million and an extension of the remaining closing deadline to September 30, 2016. The full financing was not yet completed as of the filing.
- In April 2016, the company agreed to repurchase 293,880 warrants for $1.12 million; it reports elsewhere that the repurchase was completed on June 2, 2016. The 2015 income statement included a $0.39 million gain from changes in warrant fair value, compared with a $2.87 million gain in 2014.
- Customer and supplier concentration was notable: two customers represented about 37% of 2015 continuing-operation revenue, and three suppliers accounted for about 67% of continuing-operation purchases. The top three products generated about 72% of total net revenue.
- Management disclosed ineffective disclosure controls and ineffective internal control over financial reporting, citing a material weakness related to the lack of full-time accounting personnel with U.S. GAAP experience. It described plans for training, review procedures and hiring experienced staff.
- The auditor reported a fair presentation of the 2015 and restated 2014 financial statements under U.S. GAAP. The filing also says the prior auditor could not complete its 2015 audit procedures because it lacked sufficient information, including evidence concerning timing and nature of certain write-offs and reserves.
- Risks include low cash and working capital, dependence on related-party and external financing, execution and commercialization of new products, regulatory approvals, distributor and supplier concentration, PRC currency and regulatory restrictions, and product-liability exposure. The company said it did not maintain product-liability, business-interruption, litigation or natural-disaster insurance.
- The company reported no pending or contemplated legal proceedings expected to have a significant financial effect. It had never paid cash dividends and did not expect to do so in the foreseeable future.
Important facts for investors to verify
- Confirm the issuer and period: this source is Dehaier’s FY2015 Form 20-F, not Newegg’s filing and not a quarterly report.
- Review the audited financial statements and restatement note, including asset write-downs, reserves, and discontinued-operation classification.
- Reconcile the filing’s differing descriptions of 2015 attributable net loss: audited statements report $10.22 million, while management discussion cites approximately $10.09 million.
- Verify actual completion and net proceeds of the Liaison Interactive financing, the warrant repurchase, and the company’s post-year-end liquidity position.
- Assess whether the sleep-respiratory business converted pilots and distribution relationships into commercial revenue, and whether the company had sufficient cash to fund operations and debt obligations.
- Track remediation of the disclosed control weakness and the accounting, reserve, and audit-evidence issues highlighted in the restatement and auditor-change disclosures.